ENZN
Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals Inc historical holders
total: 2
Icahn Capital Management Enzon Pharmaceuticals Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2013 Q2 or earlier
- Held for:
- 12+ quarters
- Latest activity:
- 2016 Q2
Carl Icahn has been an institutional investor in Enzon Pharmaceuticals Inc (ENZN) since at least 2013 Q2. According to 2026 Q2 report, Carl Icahn doesn't hold any shares. In our earliest available record from 2013 Q2, Icahn Capital Management held about 5.90M shares of ENZN. Since at least 2013 Q2, Icahn Capital Management has made 1 more transaction in this position.
When did Carl Icahn exit their ENZN position?
Carl Icahn no longer holds Enzon Pharmaceuticals Inc (ENZN). They sold off their entire position in 2016 Q2, closing out an investment that began in 2013 Q2.
Estimated cost basis*
- Weighted AVG buy price:
- $2.00
- Weighted AVG sell price:
- $0.47
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.